Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The differentiation of skeletal muscle is characterized by recognition, alignment, and subsequent fusion of myoblast cells at their surfaces to form large, multinucleated myotubes. Monoclonal antibodies were used to investigate antigenic changes in the cell surface membrane specific for various stages of myogenesis. Chick embryonic skeletal muscle cells were cultured in vitro to the desired stage of differentiation and then injected into BALB/c mice. Spleen cells from the immunized mice were hybridized with NS-1 or P3 8653 mouse myeloma cells. Hybrid cell clones were selected in HAT medium and screened using an indirect radioimmunoassay for the production of monoclonal antibodies specific to myogenic cell surfaces. Target cells for the radioimmunoassay included three stages of myogenesis (myoblasts, midfusion, myoblasts, and myotubes) and chick lung cells as a control for polymorphic antigens. Sixty-one clones were obtained which produced antibodies specific for myogenic cells. Thirty-five of these clones were generated from mice immunized with midfusion myoblast stages of myogenesis and 26 were obtained from mice immunized with the later myotube stage of myogenesis. Quantitative measurements by RIA of myogenic determinants per cell surface area on each target cell type revealed that most of the determinants decrease during myogenesis when midfusion myoblasts are used as the immunogen. When myotube stages are used as the immunogen, more determinants increase with cell differentiation. Therefore, the most common pattern of determinant change is for them to be present at all stages of myogenesis but to vary quantitatively through development. There are determinants unique to each stage of myogenesis and marked quantitative differences within a cell stage for each determinant.
 ...
PMID:Quantitation of changes in cell surface determinants during skeletal muscle cell differentiation using monospecific antibody. 617 92

A monoclonal antibody (Mab) named EDU-3, was produced by fusing splenocytes from one Balb/c mouse, immunized with a mixture of platelets and non-T cells from heparinized human peripheral blood, with the HAT-sensitive myeloma line P3-NS1/1.Ag4.1. By indirect immunofluorescence (IF) it was seen that this Mab reacted with all normal human platelets and bone marrow megakaryocytes, but did not react with lymphoid cells from normal donors, or platelets from Glanzmann's thrombasthenia (GT) patients. Immunoprecipitation and SDS-PAGE experiments demonstrated that this Mab recognized an epitope on the IIb-IIIa glycoprotein complex (GPC). EDU-3 inhibited platelet aggregation and release of ATP induced by ADP and epinephrine. Aggregation induced by arachidonic acid, ristocetin and bovine factor VIII were not inhibited by EDU-3. The difference between EDU-3 and other Mab directed against the IIb-IIIa GPC is discussed.
 ...
PMID:An antiplatelet monoclonal antibody that inhibits ADP and epinephrine-induced aggregation. 623 32

A recombinant plasmid vector, pSV2-neo, coding for resistance to neomycin and the related antibiotic G-418, was transfected into the mouse myeloma line X63-Ag8.653 by a modification of the protoplast fusion technique. The time interval required to obtain 10(6) G-418 resistant cells was 20 days and the efficiency was 10(-4)-10(-5), which represents a significant advantage over classical methods of selecting mutant cells bearing a dominant selection marker. To investigate the efficiency of this marker in somatic cell hybrid selection, these cells were fused to the human myeloma line U-266 and the hybrids were selected either in HAT + G-418 or HAT + ouabain. The pSV2-neo vector was as efficient as ouabain as a dominant marker with respect to the number of viable hybrid colonies selected and their levels of immunoglobulin secretion. The reciprocal experiment was also performed: HAT-sensitive, mutant U-266 cells were transfected with pSV2-neo, clones selected in G-418 and fused with X63-Ag8.653 cells, and hybrids selected in ouabain plus G-418, yielding HAT-sensitive hybrid "heteromyelomas" that were effective fusion partners with human B lymphocytes.
 ...
PMID:Somatic cell hybrid selection with a transfectable dominant marker. 632 91

Somatic cell hybrids were made between mouse myeloma cells and spleen cells derived from BALB/c female mice immunized with purified phenobarbital-induced rat liver cytochrome P-450 (PB-P-450). Hybridomas were selected in HAT medium, and the monoclonal antibodies (MAbs) produced were screened for binding to the PB-P-450 by radioimmunoassay, for immunoprecipitation of the PB-P-450, and for inhibition of PB-P-450-catalyzed enzyme activity. In two experiments, MAbs of the IgM and IgG1 were produced that bound and, in certain cases, precipitated PB-P-450. None of these MAbs, however, inhibited the PB-P-450-dependent aryl hydrocarbon hydroxylase (AHH) activity. In two other experiments, MAbs to PB-P-450 were produced that bound, precipitated and, in several cases, strongly or completely inhibited the AHH and 7-ethoxycoumarin deethylase (ECD) activities PB-P-450. These MAbs showed no activity toward the purified 3-methylcholanthrene-induced cytochrome P-450 (MC-P-450), beta-naphthoflavone-induced cytochrome P-450 (BNF-P-450) or pregnenolone 16-alpha-carbonitrile-induced cytochrome P-450 (PCN-P-450) in respect to RIA determined binding, immunoprecipitation, or inhibition of AHH activity. One of the monoclonal antibodies, MAb 2-66-3, inhibited the AHH activity of liver microsomes from PB-treated rats by 43% but did not inhibit the AHH activity of liver microsomes from control, BNF-, or MC-treated rats. The MAb 2-66-3 also inhibited ECD in microsomes from PB-treated rats by 22%. The MAb 2-66-3 showed high cross-reactivity for binding, immuno-precipitation and inhibition of enzyme activity of PB-induced cytochrome P-450 from rabbit liver (PB-P-450LM2). Two other MAbs, 4-7-1 and 4-29-5, completely inhibited the AHH of the purified PB-P-450. MAbs to different cytochromes P-450 will be of extraordinary usefulness for a variety of studies including phenotyping of individuals, species, and tissues and for the genetic analysis of P-450s as well as for the direct assay, purification, and structure determination of various cytochromes P-450.
 ...
PMID:Monoclonal antibodies to phenobarbital-induced rat liver cytochrome P-450. 633 57

The hybridoma technique, originally developed by G. Kohler & C. Milstein, is a powerful new experimental approach for analysis of complex biological systems, and is particularly suited for identification and study of surface-membrane antigens. This technique has been used for the production of monoclonal antibodies to intestinal brush border membrane proteins. Spleen cells, obtained from BALB/c mice immunized with purified brush border membranes, were fused with NSI mouse myeloma cells, and hybrids were selected with a culture medium containing hypoxanthine, aminopterin and thymidine (HAT medium). Hybridoma cultures were screened for production of specific antibodies by radio-immunobinding assays and by immunofluorescent staining of intestinal frozen sections. Selected hybridoma cultures were cloned twice and used for the production of large amounts of antibodies, which were characterized. Nineteen monoclonal antibodies have been prepared to date, about half of them specifically staining the brush border membrane of mature enterocytes. Ten of the antibodies specifically immunoprecipitate surface-membrane proteins, which were analysed by sodium dodecyl sulphate slab-gel electrophoresis, by two-dimensional slab-gel electrophoresis, and by specific enzyme assays. Two antibodies were found to be specific for sucrase-isomaltase, one for an aminopeptidase, two for an isoenzyme of alkaline phosphatase that is present exclusively in the proximal small intestine, and one for maltase-glucoamylase. These monoclonal antibodies, and others prepared by similar techniques from mice immunized with a wide variety of intestinal subcellular fractions, should prove invaluable tools for the study of the biosynthesis of cell-surface proteins, the fetal and postnatal development of specific intestinal functions, and the process of cell differentiation in the intestinal epithelium.
 ...
PMID:Use of monoclonal antibodies in the study of intestinal structure and function. 634 93

Technical aspects of generation of antibody-secreting human-human hybridomas are evaluated as based on 100 human-human fusions with a human B-lymphoma cell line (RH-L4) or the SKO-007 myeloma cell line as malignant fusion partners, and compared with similar fusion conditions in the mouse hybridoma system. The yield of hybrids was significantly lower when normal peripheral blood lymphocytes were used as fusion partners as compared with spleen lymphocytes, but could be substantially improved by increasing the amount of mitotic active B-lymphocytes by mitogen stimulation of the lymphocytes, preferably in HAT medium, prior to fusion. Furthermore, human hybrids grew slower and had a higher degree of chromosomal instability than usually observed in the mouse hybridoma system. Thus, out of 72 fusions, only 3 stable hybrids with antibody production against a predefined antigen were established. The importance of improved sources of human B-lymphocytes for human-human hybridoma production is discussed and methods of obtaining such improvement suggested.
 ...
PMID:Antibody producing human-human hybridomas. I. Technical aspects. 634 5

Six human cell lines were compared with each other and with murine myeloma NS-1 as to their sensitivity to HAT medium and their ability to form hybrids with human lymphocytes, secret monoclonal immunoglobulin, clone, and maintain detectable levels of monoclonal immunoglobulin secretion for a period of time after fusion. Fusion efficiencies varied from 0 to 50%, and the incidence of immunoglobulin secretion ranged between 1 and 78% of the hybrids. Immunoglobulin secretion of cloned hybrids varied from 0.8 to 1.6 micrograms/ml/10(6) cells among the human-human hybrids and was 2.4 micrograms/ml/10(6) cells by the human-mouse hybrid. Among the lines tested, UC729-6 and HF2 appeared optimal for pursuing further studies with human-human hybridomas. In addition, although only a small percentage of hybrids were produced with HMy2, a very high percentage secreted immunoglobulin, so that this line also warrants further investigation to improve the efficiency of hybrid formation. Implications for specific monoclonal antibody production and for therapy of leukemias and lymphomas by anti-idiotype antibodies are discussed.
 ...
PMID:Determination of the optimal human cell lines for development of human hybridomas. 635 Apr 51

Starting with a nonimmunoglobulin producing human myeloma cell line, we have constructed a human myeloma "analog" (LSM 2.7) which supports the synthesis and secretion of human immunoglobulin in vitro upon fusion with human peripheral blood and spleen mononuclear cells. Fusions between LSM 2.7 and spleen cells obtained from patients immunized against pneumococcal capsular polysaccharides consistently gave rise to hybrids which synthesized and secreted human immunoglobulin. In three of ten independent fusions a large proportion of the hybrid cultures produced specific pneumococcal antibodies. All three spleens which yielded antibody producing hybrids were from patients immunized 3 to 4 days prior to staging splenectomy for Hodgkin's disease. Antibody secreting hybrid cells ceased producing immunoglobulin 28 to 42 days post fusion. However, fusion of a HAT sensitive clone derived from a hybrid which had secreted antibody, with peripheral blood mononuclear cells, resulted in reactivation of specific antibody secretion.
 ...
PMID:Human-human hybrids secreting pneumococcal antibodies. 636 56

To assess the effects of insulin on the formation of hybridomas, sheep red blood cell (SRBC) immunized spleen cells from BALB/c mice were fused with P3U1 mouse myeloma cells. After fusion, cells were grown for 2 weeks in HAT medium containing insulin (HIAT) (doses ranging between 10(-1) to 10(-9) units/ml) or HAT medium alone. The number of hybridoma colonies was found to be significantly increased in the presence of HIAT medium compared to HAT alone. In addition, the average size of the hybridoma clones was at least doubled and the cumulative colony size index per plate increased several folds. A significant rise in the number of wells containing clones secreting anti-SRBC monoclonal antibodies was again shown in the presence of HIAT compared to HAT medium alone. The maximal effect of insulin on the above biological parameters ranged between 10(-1) and 10(-4) units/ml. It is concluded that the addition of insulin to HAT medium (HIAT) enhances hybridoma formation and thus, its more frequent use may considerably expediate ongoing research efforts on the production of monoclonal antibodies.
 ...
PMID:The addition of insulin to HAT medium (HIAT) enhances hybridoma formation. 639 29

Mouse monoclonal antibodies were prepared against DNA-cytosine-5-methyltransferase (EC 2.1.1.37) from human placenta by conventional hybridoma technology. Spleen cells from BALB/c mice immunized with highly purified enzyme were fused to X-63 Ag8.653 mouse myeloma cells. After the hybrid selection in HAT medium individual clones were screened for production of antibodies directed against the enzyme by use of solid-phase ELISA or RIA in which highly purified DNA methyltransferase was either immobilized on microtiter plates or 125I-labeled enzyme was used as a tracer. Positive clones were subcloned, re-screened in the same system and the presence of antibodies directed against DNA methyltransferase was definitively proved in a test system in which the enzyme activity was removed from the solution in immune complexes precipitated by anti mouse immunoglobulin antibodies. From more than 3800 constructed clones 8 were selected which produced antibodies against DNA methyltransferase from human placenta. These antibodies may serve as a useful tool for analysis of DNA methyltransferase structure, intracellular localization and molecular heterogeneity of this enzyme.
 ...
PMID:Preparation of monoclonal antibodies against DNA-cytosine-5-methyltransferase from human placenta. 647 79


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>